DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

Stifel Maintains Buy on Momenta Pharmaceuticals, Raises Price Target to $43

Stifel analyst Derek Archila maintains Momenta Pharmaceuticals (NASDAQ:MNTA) with a Buy and raises the price target from $29 to $43.

Benzinga · 01/28/2020 13:30

Stifel analyst Derek Archila maintains Momenta Pharmaceuticals (NASDAQ:MNTA) with a Buy and raises the price target from $29 to $43.